Health Catalyst, Inc. (NASDAQ:HCAT) Shares Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. raised its position in Health Catalyst, Inc. (NASDAQ:HCAT) by 93.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 254,762 shares of the company’s stock after purchasing an additional 123,230 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Health Catalyst were worth $1,801,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in HCAT. Fred Alger Management LLC acquired a new stake in shares of Health Catalyst in the third quarter valued at approximately $6,858,000. Portolan Capital Management LLC acquired a new stake in shares of Health Catalyst in the third quarter valued at approximately $5,402,000. Raymond James Financial Inc. acquired a new stake in shares of Health Catalyst in the fourth quarter valued at approximately $2,044,000. Martin & Co. Inc. TN increased its stake in shares of Health Catalyst by 80.0% in the fourth quarter. Martin & Co. Inc. TN now owns 490,998 shares of the company’s stock valued at $3,471,000 after purchasing an additional 218,293 shares during the period. Finally, Point72 Asset Management L.P. increased its stake in shares of Health Catalyst by 69.4% in the third quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company’s stock valued at $4,208,000 after purchasing an additional 211,805 shares during the period. Institutional investors and hedge funds own 85.00% of the company’s stock.

Insider Buying and Selling

In related news, Director Duncan Gallagher sold 4,500 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $6.98, for a total value of $31,410.00. Following the completion of the transaction, the director now owns 74,438 shares of the company’s stock, valued at approximately $519,577.24. This trade represents a 5.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Linda Llewelyn sold 6,442 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $5.80, for a total transaction of $37,363.60. Following the completion of the transaction, the insider now directly owns 92,260 shares of the company’s stock, valued at $535,108. This represents a 6.53 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 65,530 shares of company stock worth $362,167. Corporate insiders own 2.50% of the company’s stock.

Health Catalyst Stock Performance

Shares of NASDAQ:HCAT opened at $4.45 on Wednesday. The stock has a market capitalization of $312.44 million, a price-to-earnings ratio of -3.30 and a beta of 1.41. Health Catalyst, Inc. has a 1-year low of $3.76 and a 1-year high of $9.24. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The company has a 50 day moving average price of $5.32 and a 200 day moving average price of $7.02.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Stephens dropped their price target on shares of Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 6th. Royal Bank of Canada lowered their price objective on shares of Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 27th. Piper Sandler lowered their price objective on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 11th. Wells Fargo & Company lowered their price objective on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 21st. Finally, Citigroup lowered their price objective on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.27.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.